UroAlert - GU Oncology Weekly

June 04, 2026

Videos

Peer-to-Peer Clinical Conversations

Non-Surgical Management of Non-Muscle Invasive Bladder Cancer: Surveillance, Chemoablation, and Office-Based Approaches - Katie Murray

Katie Murray

Katie Murray discusses non-surgical management options for non-muscle invasive bladder cancer, covering the patient populations where TURBT can be deferred.

RAMPART Study Investigates Quality of Life Impact of Durvalumab and Tremelimumab in RCC - Sophie Merrick

Sophie Merrick

Sophie Merrick discusses patient-reported outcomes from RAMPART, evaluating adjuvant durvalumab plus tremelimumab versus observation in renal cell carcinoma.

Beyond the Abstracts

Risk of Recurrence and Progression after Endoscopic Kidney-sparing Surgery for Upper Tract Urothelial Carcinoma - Beyond the Abstract

Intraoperative Skills for Transurethral Resection of Bladder Tumor: Objective Assessment and Construct Validity of the ENTRY Metrics - Beyond the Abstract

Conference Coverage

ASCO 2026: Discussant - Is the Best yet to Come in Kidney Cancer?

ASCO 2026: Clinico-Transcriptomic Risk Stratification to Guide Abiraterone Treatment Intensification in High-Risk Prostate Cancer: A Combined Analysis of NRG/RTOG 9202, 9413, 9902, and 0521

ASCO 2026: HRQoL with Pembrolizumab or Observation for High-Risk Muscle-Invasive Urothelial Carcinoma after Surgery: Results from the AMBASSADOR Randomized Trial (Alliance A031501)

ASCO 2026: Intravesical Recombinant BCG Combined with Chemo-IO as Perioperative Therapy for Patients with MIBC: Primary Analysis of SAKK 06/19

ASCO 2026: Chemoablation with Oral Erdafitinib in Recurrent FGFR3-Altered NMIBC: A Phase II Window-of-Opportunity Trial

Articles

Editor Selected Abstracts and Commentaries

Bladder Cancer

10-yr Outcomes of Senior Clinical Fellowship in Robot-assisted Radical Cystectomy (RARC) with focus on Intracorporeal Ileal Conduit Urinary Diversion: Aggregated Learning Curve Assessment and Achievement of the EAU-Robotic Urology Section (ERUS) RARC Curr

An advanced in vitro bladder cancer model integrating bladder cancer spheroids into a healthy human urothelium for preclinical therapeutic testing.

A machine-learning approach to predict additional treatment after Bacillus Calmette-Guérin induction in non-muscle-invasive bladder cancer.

Evolution of treatment and oncological outcomes in patients undergoing radical cystectomy: a comparative analysis across two decades at a tertiary center.

Radiogenomic analysis of muscle-invasive bladder cancer using CT-based texture analysis.

Neoadjuvant Sacituzumab Govitecan in Patients With Muscle-Invasive Bladder Cancer: Primary Results of the SURE-01 Trial.

What's next for VI-RADS? Updates and future perspectives from the ACR VI-RADS steering committee.

Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment in Metastatic Urothelial Cancer: A Randomized Phase II Study of Two Alternative Dosing Schedules.

Decoding Immune Mechanisms in BCG-unresponsive Non-muscle Invasive Bladder Cancer.

Unmet Treatment Need and Challenges Associated with Comparative Evidence Generation in BCG-unresponsive Non-muscle-invasive Bladder Cancer: An Expert Consensus.

AI-MIRACLE: Artificial Intelligence and MultIpaRAmetric MRI Predict CLinical OutcomEs to Neoadjuvant Immunotherapy in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy.

Computed tomography-derived extracellular volume fraction is associated with high-grade recurrence in non-muscle-invasive bladder cancer treated with intravesical gemcitabine and docetaxel.

Real-world Patterns and Trends of Intravesical Chemotherapy for Non-muscle Invasive Bladder Cancer: Insights from a Large Prospective German Cohort.

Durvalumab and BCG Approved for Treating High-Risk NMIBC

Penile & Urethral Cancers

Comparison of PET imaging of [18F]F-FAPI and [18F]F-FDG for diagnosis of suspected lymph node metastases in penile squamous cell carcinoma: a prospective pilot study.

Surgical Margin Status and Minimal Margin Width in Penile Squamous Cell Carcinoma: Local Recurrence and Survival Outcomes in a Single-Centre Cohort.

Renal Cancer

Comparative effectiveness and cost-effectiveness of an artificial intelligence workflow for small renal mass diagnosis on computed tomography.

Cancer-Associated Fibroblasts Promote Development of Papillary Renal Cell Carcinoma by Inducing Histone Lactylation of RBM15B to Modify in an m6A-Dependent Manner on ANLN.

Co-overexpression of ELOVL2 and ELOVL5 promotes clear cell renal cell carcinoma progression through LIMK1-mediated cytoskeletal reorganization.

Survival Trends in Metastatic Renal Cell Carcinoma Across Therapeutic Eras and Histologic Subtypes.

Percutaneous thermal ablation versus robot-assisted partial nephrectomy for localized renal cell carcinoma: a systematic review and meta-analysis stratified by tumor complexity.

Should Metastatic Site Inform First-Line Therapy in Clear Cell Renal Cell Carcinoma?

Bayesian Evaluation of Treatment Effect of Avelumab Plus Axitinib for Advanced Renal Cell Carcinoma.

Sex-Specific Adverse Events and Cardiovascular Toxicity of Cabozantinib in Renal Cell Carcinoma: A Nine-Year Pharmacovigilance Study.

Joint effects and dynamic trajectories of metabolic insulin resistance and systemic inflammation in the risk of renal cell carcinoma: a UK Biobank cohort analysis.

Natural Products in Clear Cell Renal Cell Carcinoma: Rewiring the VHL-HIF Axis, Metabolic Plasticity, and Tumor-Immune Interactions.

Prostate Cancer

Progression-free survival following primary staging with [¹⁸F]PSMA-1007-PET/ceCT versus Na[¹⁸F]F-PET/ceCT in prostate cancer: Results from the PRISMA-PET randomized controlled trial

Population-adjusted network meta-analyses provide new insights into the efficacy of treatment alternatives for metastatic castration-sensitive prostate cancer.

USP2 is an androgen-repressed survival factor that stabilises oncoproteins to facilitate therapy resistance in prostate cancer.

GWAS from a multicenter prospective study of radium-223 in bone-metastatic castration-resistant prostate cancer.

Comparative functional, perioperative and oncological outcomes of robot-assisted and open radical prostatectomy: a systematic review and meta-analysis.

Beyond GnRH analogues: The Renaissance of Estrogens in Prostate Cancer Management.

Pathogenic Germline Variants in a Racially Diverse Real-World Cohort of Patients With Prostate Cancer.

One-Year Functional Satisfaction and Quality of Life Outcomes of Patients With a History of Radiotherapy With Artificial Urinary Sphincters.

New prostate cancer risk groups by PSMA-PET (PPP3): an international, retrospective, registry-based cohort study.

Impact of radiotherapy timing on survival and radiotoxicity outcomes in localized prostate cancer: a retrospective cohort study.

Phase 1b trial of Bavdegalutamide (ARV-110) in combination with Abiraterone for metastatic prostate cancer.

One-year Follow-up after US-guided Transperineal Focal Laser Ablation of Localized Prostate Cancer: Worldwide Registry Study.

Real-World Clinical and Economic Outcomes Among Patients with Localized Prostate Cancer Undergoing Radical Prostatectomy Across Different Risk Stratifications in the United States.

Impact of Absolute PSA Value and Relative PSA Response Rate on Overall Survival in Patients With Metastatic Castration-Sensitive Prostate Cancer Treated With Androgen Receptor Signaling Inhibitors.

Aglatimagene besadenovec (CAN-2409) with radiotherapy for patients with localised prostate cancer: a phase 3, multicentre, randomised, double-blind, placebo-controlled trial.

Perioperative Apalutamide in High-Risk Localized Prostate Cancer.

Ceralasertib Monotherapy in Patients with ATM-Altered Advanced Solid Tumors or Metastatic Castration-Resistant Prostate Cancer: Data from the Phase 2a PLANETTE Study.

Radionuclide Combination Strategies in Prostate Cancer: Insights from the AlphaBet Trial.

Phase I design for partially ordered groups with late-onset toxicity.

PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate Cancer.

Real-World Treatment Patterns for Patients with High-Risk Biochemically Recurrent Nonmetastatic Castration‑Sensitive Prostate Cancer.

Comparison of platinum and gold fiducial markers for prostate radiotherapy: a phantom study.

PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate Cancer

Perioperative Apalutamide in High-Risk Localized Prostate Cancer

Top advances of the year: Radiopharmaceutical therapy for prostate cancer.

Success and Limitations of PSMA RLT : The Nuclear Medicine View.

ISUP 2 prostate cancer with suspicion of extraprostatic extension on MRI: Prostatectomy results and oncologic outcomes.

Development and External Validation of a Machine Learning-Based Risk Classification Score for Prostate Cancer-Specific Cardiovascular Risk.

Prostate Cancer Treatment Patterns and Inequities Among Racial Groups in Brazil's Public Health System: Insights From a 16-Year Real-World Study.

Serum micronutrient levels in men with prostate carcinoma: An observational study at a tertiary care health facility.

Increasing and more consistent use of pre-biopsy MRI in prostate cancer diagnosis: insights from a population-based study in the Netherlands.

A forward genetic screen identifies Sirtuin1 as a driver of neuroendocrine prostate cancer.

Trial protocol: RadTARGET, a multicenter phase II randomized controlled trial evaluating focal radiotherapy boost with de-intensification of dose to non-suspicious prostate in patients with intermediate- or high-risk prostate cancer.

Comparison of the Swedish and Finnish Centers in the European Randomized Study of Screening for Prostate Cancer (ERSPC).

Polygenic risk score with KLK3 SNP-SNP interaction pairs for predicting prostate cancer aggressiveness.

Comparative analysis of genitourinary toxicity following bladder outlet obstruction procedures in patients before versus after radiotherapy for localized prostate cancer: a retrospective cohort study using the TriNetX database.

Associations Between Medicaid Insurance, Facility Medicaid Share, and Guideline-Concordant Prostate Cancer Care - Beyond the Abstract

Upper Tract Tumors

Machine learning-based integration of systemic immune-inflammation and nutritional signatures for predicting disease-free survival in upper tract urothelial carcinoma: a multicenter study.

Robotic versus laparoscopic radical nephroureterectomy for upper tract urothelial carcinoma: comparable oncologic outcomes with reduced intravesical recurrence in pathological T3 disease.

Immunotherapy for Upper Tract Urothelial Carcinomas: A 2026 Update.

Testicular Cancer

Long-Term Clinical Outcomes of Advanced Germ Cell Tumors: Experience From 105 Patients Over 20 Years.

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2026 Digital Science Press, LLC